PD-L1 Anti-PD-L1 Antibodies and Their Use as Therapeutics and Diagnostics

摘要

The present invention relates to an antibody-antigen binding domain that specifically binds Programmed Death-1 (PD1, PdcL1), and more specifically, to a domain composed of a specific CDR combination, and more specifically, a specific antibody named as a specific system ( Ab), heavy chain (HC) or light chain (LC). The present invention also relates to antibodies that inhibit cellular signaling and activity in the immune mediated by PD-L1, of these antibodies for treating or diagnosing cancer, epidemics or other pathological diseases regulated by PD-L1 mediated functions. It is about use. The composition of the present invention is useful for the treatment of cancer, neurodegenerative and infectious, particularly viral diseases and other conditions, which are components of inappropriate or deleterious expression and/or etiology or pathology of human PD-1. Accordingly, the present invention provides a method of treating cancer with the anti-PD-L1 protein of the present invention or inhibiting tumor progression in a subject in need thereof, and the humanized anti-PD-1 mAb provides disease progression, in particular cancer and It is used as a therapeutic agent to treat human diseases related to immune cell suppression by PD-L1-mediated intracellular signaling leading to viral infection.